Press Releases

 

Company News

  Date Title and Summary View
Sep 7, 2016
Optima, a Global Phase III Study in Newly Diagnosed Primary Liver Cancer Patients Ovation, a Study of Gene-mediated Immuno-therapy in 1st line Ovarian Cancer LAWRENCEVILLE, N.J., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Mr. Michael H. Tardugno, Chairman and CEO and Mr. Jeffrey W. Church, Sr. ...
Aug 15, 2016
Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses Company to Hold Conference Call on Monday, August 15, 2016 at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today...
Aug 15, 2016
Subgroup Data Continue to Show a Statistically Significant Improvement in Overall Survival, Consistent With a Two Year Median Survival Benefit Following Treatment with ThermoDox® plus Optimized RFA Data from the Chinese Cohort of Patients Show Clinically Meaningful Benefit LAWRENCEVILLE, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Celsion...
Aug 9, 2016
LAWRENCEVILLE, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, announced today that it has signed a long-term Technology Transfer, Manufacturing and Commercial Supply Agreement (the "Agreement") with Zhejiang Hisun Pharmaceutical Co. Ltd. (SSE Code:600267), a leading pharmace...
Aug 8, 2016
LAWRENCEVILLE, N.J., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter and six-month period ended June 30, 2016 and provide an update on its development programs for ThermoDox®, its proprietary heat-activated liposomal ...
Jul 25, 2016
LAWRENCEVILLE, N.J., July 25, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced data from the second cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with adv...
Jul 11, 2016
LAWRENCEVILLE, N.J., July 11, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation¬†(NASDAQ:CLSN) today announced that its ongoing Phase III OPTIMA trial evaluating ThermoDox® in primary liver cancer, also known as hepatocellular carcinoma or HCC, was featured during an oral presentation at the 7th Asia-Pacific Primary Liver Cancer Expert (APPLE) Mee...
Jul 7, 2016
LAWRENCEVILLE, N.J., July 07, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that Michael H. Tardugno, chairman, president and chief executive officer, will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 9:30 a.m. ET. The conference will be held at Le Parker Meridien in N...
Jun 21, 2016
Ongoing Phase III Trial to Confirm Hypothesis That The Combination of Standardized Radio Frequency Ablation (sRFA) Plus Lyso-Thermosensitive Liposomal Doxorubicin (LTLD) May Substantially Increase Survival of Patients with HCC Compared to sRFA Alone LAWRENCEVILLE, N.J., June 21, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) toda...
Jun 13, 2016
LAWRENCEVILLE, N.J., June 13, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor to purchase an aggregate of approximately $6 million of shares of common stock, or pre-funded warrants in lieu thereof, i...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Share This